Trademark Overview
On Tuesday, January 20, 2026, a trademark application was filed for MIRALOCK with the United States Patent and Trademark Office. The USPTO has given the MIRALOCK trademark a serial number of 99605203. The federal status of this trademark filing is NEW APPLICATION - RECORD INITIALIZED NOT ASSIGNED TO EXAMINER as of Tuesday, January 20, 2026. This trademark is owned by Mirador Therapeutics, Inc.. The MIRALOCK trademark is filed in the Chemical Products, Pharmaceutical Products, and Computer & Software Services & Scientific Services categories with the following description:
Research, development and consultation related thereto in the medical, pharmaceutical research and biotechnology fields; Pharmaceutical research and development of pharmaceutical preparations; Research and development services in the fields of human and animal pharmaceutical and biotechnology drug development and manufacture; Laboratory research services in connection with developing new medicinal products; Scientific research, development and consultation services in the fields of immunology, antibodies, vaccines, medicine, biotherapeutics, and therapeutics
Pharmaceutical preparations for the diagnosis, prevention, or treatment of inflammation and immunology disorders or diseases, autoimmune diseases, cancer, and other diseases of the immune systems, digestive systems, skin, joint, lung, liver, kidney, bile duct, nervous systems, or gastrointestinal systems; Diagnostic preparations for medical purposes; Diagnostic kits consisting primarily of monoclonal antibodies for use in disease testing; Chemical, biological and biochemical reagents for medical or veterinary purposes; Diagnostic test kits comprised of medical diagnostic reagents and assays that test for the presence of antigens, pathogens, biomarkers for diseases, or biomarkers for predicting patients' response to therapeutic agents
Chemical substances, chemical materials and chemical preparations for scientific purposes; Active pharmaceutical ingredients, namely, antibodies, proteins and small molecules for use in the manufacture of pharmaceuticals, biopharmaceuticals, vaccines, and finished drug products for the diagnosis, prevention, or treatment of inflammation and immunology disorders or diseases, autoimmune diseases, cancer, and other diseases of the immune systems, digestive systems, skin, joint, lung, liver, kidney, bile duct, nervous systems, or gastrointestinal systems; Antibodies for use in the manufacture of active ingredients of pharmaceuticals and vaccines
